About harrow - HROW
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
HROW At a Glance
Harrow, Inc.
102 Woodmont Boulevard
Nashville, Tennessee 37205
| Phone | 1-615-733-4730 | Revenue | 130.19M | |
| Industry | Pharmaceuticals: Major | Net Income | -24,411,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 46.953% | |
| Fiscal Year-end | 12 / 2024 | Employees | 315 | |
| View SEC Filings |
HROW Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.806 |
| Price to Book Ratio | 5.598 |
| Price to Cash Flow Ratio | 95.132 |
| Enterprise Value to EBITDA | 36.586 |
| Enterprise Value to Sales | 3.631 |
| Total Debt to Enterprise Value | 0.403 |
HROW Efficiency
| Revenue/Employee | 413,311.111 |
| Income Per Employee | -77,495.238 |
| Receivables Turnover | 3.568 |
| Total Asset Turnover | 0.555 |
HROW Liquidity
| Current Ratio | 2.818 |
| Quick Ratio | 2.598 |
| Cash Ratio | 1.677 |
HROW Profitability
| Gross Margin | 69.553 |
| Operating Margin | 0.445 |
| Pretax Margin | -18.389 |
| Net Margin | -18.75 |
| Return on Assets | -10.407 |
| Return on Equity | -49.843 |
| Return on Total Capital | -9.358 |
| Return on Invested Capital | -12.231 |
HROW Capital Structure
| Total Debt to Total Equity | 270.765 |
| Total Debt to Total Capital | 73.029 |
| Total Debt to Total Assets | 61.106 |
| Long-Term Debt to Equity | 269.619 |
| Long-Term Debt to Total Capital | 72.72 |